<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://hdl.handle.net/123456789/1960">
<title>CHEMOPREVENTIVE EFFECTS OF ROOT BARK EXTRACT OF C. PORTORICENSIS (BENTH.) IN N-NITROSO-N-METHYLUREA AND BENZO(A)PYRENE-INDUCED MAMMARY GLAND AND REPRODUCTIVE TOXICITY IN WISTAR RATS</title>
<link>http://hdl.handle.net/123456789/1960</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://hdl.handle.net/123456789/1961"/>
</rdf:Seq>
</items>
<dc:date>2026-04-19T05:07:05Z</dc:date>
</channel>
<item rdf:about="http://hdl.handle.net/123456789/1961">
<title>CHEMOPREVENTIVE EFFECTS OF ROOT BARK EXTRACT OF C. PORTORICENSIS (BENTH.) IN N-NITROSO-N-METHYLUREA AND BENZO(A)PYRENE-INDUCED MAMMARY GLAND AND REPRODUCTIVE TOXICITY IN WISTAR RATS</title>
<link>http://hdl.handle.net/123456789/1961</link>
<description>CHEMOPREVENTIVE EFFECTS OF ROOT BARK EXTRACT OF C. PORTORICENSIS (BENTH.) IN N-NITROSO-N-METHYLUREA AND BENZO(A)PYRENE-INDUCED MAMMARY GLAND AND REPRODUCTIVE TOXICITY IN WISTAR RATS
ADEFISAN, ADEDOYIN OMOBOLANLE
Breast cancer (BC) remains a disease with high morbidity and mortality. In Nigeria,&#13;
BC represents about 23% of all cancer cases. Currently available chemotherapeutic&#13;
interventions are associated with significant adverse effects, hence the need for safer&#13;
options. C. portoricensis (CP) has been applied to manage breast diseases in&#13;
ethnomedicine. However, there is paucity of scientific basis to justify this claim. In this&#13;
study, an investigation of the effects of CP on N-nitroso-N-methylurea (MNU) and&#13;
Benzo(a)pyrene (BP)-induced mammary and reproductive organ toxicity in Wistar rats&#13;
was conducted.&#13;
A root bark sample of CP was taken from Ikire, Osun State and authenticated at Forest&#13;
Hebarium Ibadan (FHI:111949). The methanol extract of CP (MCP) was obtained&#13;
from the powdered root. The MCP was partitioned to obtain n-hexane, chloroform,&#13;
ethylacetate and butanol fractions. The chloroform fraction of CP (CCP) was subjected&#13;
to biochemical assay using MCF-7 cells. Sixy-four female Wistar rats (30-40g) were&#13;
divided into eight groups (n=8): Vehincle, MNU, [MNU+MCP (100 mg/kg)],&#13;
[MNU+MCP (200 mg/kg)], [MNU+MCP (300 mg/kg)], MCP (300 mg/kg),&#13;
[MNU+Vincasar (0.5 mg/kg)] and Vincasar only. In another study, fifty-six female&#13;
rats were grouped into seven (n=8): Vehincle, [MNU+BP], [MNU+BP+CCP (50&#13;
mg/kg)], [MNU+BP+CCP (100 mg/kg)], CCP (100 mg/kg), [MNU+BP+ Vincasar]&#13;
and Vincasar only. The MNU (50 mg/kg) and BP (50 mg/kg) were administered&#13;
intraperitoneally at age 7, 10 and 13 weeks. The MCP and CCP were administered&#13;
orally thrice weekly. Rats were sacrificed; blood and tissues (mammary and uterine)&#13;
were obtained for analyses. Lactate dehydrogenase (LDH), Superoxide Dismutase&#13;
(SOD), Catalase, Glutathione-S-Transferase (GST), Glutathione Peroxidase (GPx),&#13;
malondialdehyde, Nitric Oxide (NO) and Myeloperoxidase were determined by visspectrophotometry. Cyclooxygenase-2, inducible Nitric Oxide Synthase (iNOS), B-cell&#13;
lymphoma-2 (Bcl-2), p53, Interleukins-1β and 6 (IL-1β, IL-6), Estrogen and&#13;
Progesterone receptors (ER+, PR+) and Epidermal Growth Factor Receptor-2 (EGFR-&#13;
2) were determined by immunohistochemistry. Micro-section of tissues were subjected&#13;
to Hematoxylin &amp; Eosin and examined under the light microscope. Data were analysed&#13;
using ANOVA at α0.05.ix&#13;
The CCP decreased levels of IL-1β (34%), LDH (24%), MPO (74%), malondialdehyde&#13;
(55%) and increased the activities of SOD (48%) and catalase (49%) in MCF-7 cells.&#13;
The MNU decreased activities of mammary SOD (22%), uterine CAT (24%) and, GST&#13;
(25%) relative to Vehincle. The MCP (100 mg/kg) when compared with MNU&#13;
significantly elevated mammary SOD (18%) and uterine GST (20%). Treatment with&#13;
CCP (100 mg/kg) when compared with MNU+BP significantly increased the&#13;
mammary catalase (24.42±4.86 vs 16.1p6±2.90), GPx (171.48±13.97 vs 93.68±5.06),&#13;
SOD (25.16±4.34 vs 16.09±2.90) and uterine catalase (29.52±4.83 vs 15.04±2.41) and&#13;
SOD (48.56±4.70 vs 21.42±0.35), respectively. Additionally, CCP (100 mg/kg)&#13;
significantly decreased mammary and uterine MPO (73%, 57%), NO (21%, 26%) and&#13;
malondialdehyde (10%, 31%) when compared with [MNU+BP]-treated rats. The CCP&#13;
(100 mg/kg) decreased ER+, PR+, EGFR-2, cyclooxygenase-2, iNOS, IL-6, IL-1β, Bcl-&#13;
2 and increased p53 expression in the mammary tissues of [MNU+BP+CCP]-treated&#13;
rats. Histology of mammary tissues showed atypical epithelia, high nucleocytoplasm&#13;
and ductal carcinoma in MNU+BP rats, which were reversed in rats given CCP (100&#13;
mg/kg).&#13;
C. portoricensis demonstrated chemopreventive effects via induction of apoptosis and&#13;
reduction of inflammatory cytokines.
</description>
<dc:date>2023-02-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
